Literature DB >> 9267782

Prostate cancer: indicators of aggressiveness.

W A Sakr1, D J Grignon.   

Abstract

In spite of the slow progression rates common to most prostate cancers, it is well recognized that a subset of patients will experience a more aggressive course with many losing their lives to this malignancy. As the number of patients diagnosed with prostate cancer continues to increase, there is a growing pressure to refine and supplement the three most important prognostic parameters for this disease (tumor pathologic stage, its histologic differentiation (Gleason score) and the level of prostate specific antigen). While this review emphasizes the value of these factors in stratifying patients into risk groups, it also explores the prognostic significance of additional commonly used and evolving non-traditional markers (DNA ploidy, proliferation, tumor angiogenesis, and the status of tumor suppressor genes).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267782

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Genomewide scan for prostate cancer-aggressiveness loci.

Authors:  J S Witte; K A Goddard; D V Conti; R C Elston; J Lin; B K Suarez; K W Broman; J K Burmester; J L Weber; W J Catalona
Journal:  Am J Hum Genet       Date:  2000-05-24       Impact factor: 11.025

Review 2.  Growth hormone and prostate cancer: guilty by association?

Authors:  A Grimberg; P Cohen
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

Review 3.  Molecular pathology of prostate cancer.

Authors:  C Hughes; A Murphy; C Martin; O Sheils; J O'Leary
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

Review 4.  The use of zebrafish model in prostate cancer therapeutic development and discovery.

Authors:  Haneen Amawi; Alaa A A Aljabali; Sai H S Boddu; Sadam Amawi; Mohammad A Obeid; Charles R Ashby; Amit K Tiwari
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

5.  Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?

Authors:  Alvin R Cabrera; Fergus V Coakley; Antonio C Westphalen; Ying Lu; Shoujun Zhao; Katsuto Shinohara; Peter R Carroll; John Kurhanewicz
Journal:  Radiology       Date:  2008-05       Impact factor: 11.105

6.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study.

Authors:  Jeffrey C Weinreb; Jeffrey D Blume; Fergus V Coakley; Thomas M Wheeler; Jean B Cormack; Christopher K Sotto; Haesun Cho; Akira Kawashima; Clare M Tempany-Afdhal; Katarzyna J Macura; Mark Rosen; Scott R Gerst; John Kurhanewicz
Journal:  Radiology       Date:  2009-04       Impact factor: 11.105

7.  Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.

Authors:  Danil V Makarov; Cameron Marlow; Jonathan I Epstein; M Craig Miller; Patricia Landis; Alan W Partin; H Ballentine Carter; Robert W Veltri
Journal:  Prostate       Date:  2008-02-01       Impact factor: 4.104

8.  Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer.

Authors:  E O Olapade-Olaopa; D K Moscatello; E H MacKay; T Horsburgh; D P Sandhu; T R Terry; A J Wong; F K Habib
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.